Overview
Location
United States, Washington, Seattle
Employees
11-50
Total raised
$81M
Founded date
2008
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jul 26, 2010 | Series B round | $32M |
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 8, 2017 | #ESMO17 ROUNDUP: Merck’s data on Keytruda/chemo combo for lung cancer takes early spotlight at ESMO | MADRID — Merck’s abstract $MRK on its big study of Keytruda (pembrolizumab) combined with chemo hit early at ESMO, attracting considerable attention for the impressive progression-free survival data the pharma giant p... |
| Jun 29, 2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| Dec 23, 2013 | Deals of the Year: The top 28 venture capital investments we tracked in 2013 | Venture capital investing in Washington state started out with a whimper in 2013, but it is ending with a bang. After the slow start, as evidenced by the chart above from CB Insights in which just $100 million was invested in the first quar... |
| Oct 30, 2013 | Immune Design Closes an up to $49M Series C Financing | Immune Design, a Seattle, WA-based biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, closed an up to $49m Series C financing. The round was led by The Column Group and ... |
| Oct 30, 2013 | Immune Design Raises Up to $49M Series C | SEATTLE, WA, Biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced it has closed a Series C financing totaling up to $49 million. >> Click here for... |
| Oct 30, 2013 | Immune Design Grabs $32.5M, Cashing in on Cancer Immunotherapy Rush | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Seattle-based Immune Design imagines growing into one of the next big players in immunotherapy for cancer, and today it’s secured some big venture bucks to see if it can deliv... |
| Oct 30, 2013 | Immune Design recruits new team, lands $32.5M for cancer immunotherapies | Immune Design CEO Carlos Paya Over the last few months, Carlos Paya has been filling out his management team at Seattle-based Immune Design. And today the biotech CEO detailed an injection of $32.5 million in venture cash--with the near-ter... |
| Jul 26, 2010 | Immune Design Secures $32M in Series B Financing | Immune Design Corp., a Seattle, WA-based biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer, has secured $32m in Series B financing. The investment was led by ProQuest Investment... |
| Jun 20, 2008 | Vaccsys raises $9 million for vaccine research | Vaccsys, a company that does vaccine research, has raised $9 million of a planned $18 million round from Alta Partners, Versant Venture Capital and The Column Group. Vaccsys’s web site is here, although it’s still under construction. Update... |